Business Wire

Booking.com and Antom Partner to Expand Local Payment Options Across Asia

Share

Strategic partnership to streamline payment solutions and elevate traveller experience, introducing over 40 new payment methods across 8 key Asian markets

Booking.com, one of the world’s leading travel companies, and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership which will enhance the payment experience for Booking.com customers by integrating diverse payment options across key markets in Asia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114445080/en/

This partnership will enable Booking.com to deliver a more tailored customer experience while unlocking business opportunities across China’s Hong Kong SAR, Indonesia, Japan, Malaysia, Singapore, South Korea, Thailand, and the Philippines — markets with a combined population of approximately 680 million. Each market presents distinct challenges, including varying payment methods, currencies and regulatory frameworks. Antom helps global merchants like Booking.com navigate this complexity by leveraging its extensive payment channel partnerships and deep knowledge of local payment landscapes.

Antom has established local acquiring capabilities in over 40 countries and regions, enabling businesses to integrate hundreds of payment methods and supports transactions in over 100 currencies. It offers businesses seamless access to a diverse range of global payment options, including credit cards, e-wallets, and local payment solutions. By leveraging AI technology, Antom helps merchants enhance transaction security, optimise foreign exchange risk management, reduce costs, and improve operational efficiency through real-time payments and blockchain solutions. Additionally, Antom provides digitisation and digital marketing solutions to support merchants’ business growth.

Booking.com is committed to making it easier to experience the world, with a smooth and seamless payment process being a key factor in enabling travellers to book with ease and confidence. Through its partnership with Antom, the digital travel platform will make over 40 payment options available over time, including online banking, bank transfers, digital wallets and local card payments. Key mobile wallets such as AlipayHK (Hong Kong SAR, China), Boost (Malaysia), GCash (the Philippines), GrabPay (Singapore), Kakao Pay (South Korea), Naver Pay (South Korea), Touch 'n Go eWallet (Malaysia) and TrueMoney (Thailand) will be the first to be introduced as new payment methods. This added flexibility empowers a wider range of customers to use their preferred payment methods, streamlining the checkout process and ensuring quicker, more seamless transactions - ultimately unlocking travel opportunities for more consumers across Asia Pacific.

By integrating Antom’s multi-currency offerings and cross-border settlement capabilities, Booking.com is empowering its global accommodation providers to expand user reach, and optimise payment acceptance and reconciliation across diverse markets. This collaboration will especially benefit smaller properties and holiday rentals that may lack access to traditional payment infrastructures, enabling them to compete more effectively in the global marketplace.

Daniel Marovitz, Senior Vice President of Fintech, at Booking.com commented, "Partnering with Antom allows us to streamline and enhance the payment experience for our travellers across Asia Pacific, integrating a wider range of local payment options that align with regional preferences. This collaboration reflects our commitment to delivering a seamless travel experience from booking to checkout. We look forward to working with Antom to support local businesses and continue advancing a more connected, innovative payment ecosystem for travel."

“We’re excited to partner with Booking.com to expand payment options, broaden customer reach across diverse markets, and support the platform in better serving the unique needs of each region,” said Gary Liu, General Manager of Antom, Ant International. “This partnership reflects our commitment to making payments more efficient and enabling merchants to unlock new growth opportunities in today’s dynamic landscape.”

About Booking.com
Part of Booking Holdings Inc. (NASDAQ: BKNG), Booking.com’s mission is to make it easier for everyone to experience the world. By investing in the technology that helps take the friction out of travel, Booking.com’s marketplace seamlessly connects millions of travellers with memorable experiences every day. For more information, follow @bookingcom on social media or visit globalnews.booking.com.

About Antom
Ant International’s Antom is the leading payment and digitisation services provider for merchants around the world. It offers one-stop, vertical-specific digital payment solutions to meet the payment needs of merchants of all sizes. Antom has established local acquiring capabilities in over 40 markets, with the flexibility to accept payments in more than 100 currencies. It also provides digital marketing solutions and merchant digitisation services to help merchant in digital operations and to better engage with their customers. To learn more, please visit https://www.antom.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114445080/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye